SLSN

SOLESENCE, INC.

Nasdaq · Perfumes, Cosmetics & Other Toilet Preparations · Inc. DE · CIK 0000883107
$1.21 -3.97% $89.0M
4 New Institutional Positions
Vol
Market Cap$89.0M
Cap SizeMicro Cap
Inst. Holders6 funds
Inst. Value$1.9M
Inst. Activity4 buys / 0 sells
SEC Reports5
Press Releases2
Exchange Nasdaq·Sector Perfumes, Cosmetics & Other Toilet Preparations·Inc. DE·CIK 0000883107·Prev Close $1.26

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$1.7MNEW
CHARLES SCHWAB INVESTMENT MANAGEMENT$75.6KNEW
MORGAN STANLEY$56.3KDOUBLED
WELLS FARGO & COMPANY/MN$33.1KADD
BANK OF AMERICA CORP$18.6KDOUBLED
6 institutional holders with $1.9M total value (1,164,421 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net buying activity: 4 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC1,048,394$1.7M90.0%NEW
2CHARLES SCHWAB INVESTMENT MANAGEMENT INC47,387$75.6K4.1%NEW
3MORGAN STANLEY35,288$56.3K3.0%DOUBLED +123.5%
4WELLS FARGO & COMPANY/MN20,773$33.1K1.8%ADD +48.9%
5BANK OF AMERICA CORP /DE/11,657$18.6K1.0%DOUBLED +111.5%
6FMR LLC922$1.5K0.1%DOUBLED +674.8%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
MORGAN STANLEYDOUBLED15,79135,288+123.5%$56.3K2025-Q4
WELLS FARGO & COMPANY/MNADD13,95420,773+48.9%$33.1K2025-Q4
BANK OF AMERICA CORP /DE/DOUBLED5,51111,657+111.5%$18.6K2025-Q4
FMR LLCDOUBLED119922+674.8%$1.5K2025-Q4
UBS Group AGADD12,23919,050+55.6%$61.3K2025-Q3
MORGAN STANLEYTRIM32,82415,791-51.9%$50.8K2025-Q3
VANGUARD GROUP INCNEW940,848$4.1M2025-Q2
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW47,387$206.6K2025-Q2
MORGAN STANLEYNEW32,824$143.1K2025-Q2
UBS Group AGNEW12,239$53.4K2025-Q2
WELLS FARGO & COMPANY/MNNEW12,120$52.8K2025-Q2
BANK OF AMERICA CORP /DE/NEW6,028$26.3K2025-Q2

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
2024-12-31
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 19, 2026
routine
Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Allē Awards, Marking Fourth Year of Recognition
<p align="center">      <em> SPF-Infused Concealer Featuring Kleair™</em>,<em> WHSPR™</em>,<em> and Chromalüm™ Recognized Across <br>Anti-Aging, Color
May 14, 2026
other
Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition
<p align="center"><em>The report, led by the United Kingdom’s APPG for Beauty, Hair &amp; Wellbeing, calls for a national strategy to combat UV exposu
May 12, 2026
earnings
Solésence Reports First Quarter 2026 Financial Results
<p align="center"><em>Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commerc
May 12, 2026
earnings_calendar
SLSN Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
other
Solésence Launches New Skin Health Technologies: WHSPR™ and Chromalüm™
<p align="center"><em>New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environm
May 4, 2026
earnings_calendar
SLSN Q1 2026 Earnings Scheduled — 2026-05-04
Apr 28, 2026
earnings
Solésence To Report First Quarter 2026 Financial Results and Host a Conference Call on May 12
<p>ROMEOVILLE, Ill., April 28, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions acro
Apr 27, 2026
other
Solésence, Inc. Announces Appointment of New Independent Director
<p align="center"><em>Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees</em></p>
Mar 31, 2026
earnings
Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results
<p align="center"><em>Full Year 2025 record revenue of $62.1 million</em></p>
Mar 31, 2026
earnings_calendar
SLSN Q4 2025 Earnings Scheduled — 2026-03-31
Mar 19, 2026
earnings
Solésence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026
<p align="left">ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care s